Follow-up of two cases of suspected interstitial lung disease following severe COVID-19 infection shows persistent changes in imaging and lung function

Ivan Cherrez-Ojeda1,2 | Karla Robles-Velasco2 | Maria F. Osorio2 | Vincent Cottin3 | José Vergara Centeno1,4 | Miguel Felix1,2

Abstract
Physicians are observing persisting symptoms and unexpected organ dysfunction after severe COVID-19. In this report, we present the follow-up of two cases of suspected interstitial lung disease following the viral infection. Up to the last month of follow-up, both patients presented with persistent changes in imaging and pulmonary function tests.

Keywords
computed tomography, COVID-19, DLCO, follow-up, pulmonary function tests

1 Universidad Espíritu Santo, Samborondón, Ecuador
2 Respiralab Research Group, Guayaquil, Ecuador
3 National Coordinating Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, Hospices Civils de Lyon, Claude Bernard University Lyon, Lyon, France
4 Hospital General Guasmo Sur, Guayaquil, Ecuador

Correspondence
Ivan Cherrez-Ojeda, Universidad Espíritu Santo, Km. 2.5 Vía La, Puntilla Samborondón 0901-952, Ecuador. Email: ivancherrez@gmail.com

Funding information
This research was partially funded by an unrestricted grant provided by Universidad Espíritu Santo, Ecuador. The sponsor had no role in the design and development of the manuscript

1 of 5
2 | CASE REPORT

2.1 | Case 1

A 72-year-old woman presented to the emergency department (E.R) with a weeklong history of malaise, headache, and dry cough. She had been recently experiencing worsening of her symptoms together with chest pain. Her past medical history was notable for osteoporosis, osteoarthritis, and nonallergic rhinitis. Upon physical examination, fine bilateral velcro-like crackles were heard at the lung bases, together with a low oxygen saturation (60% on room air), which prompted her admission. Her laboratory results were remarkable for elevated inflammatory markers and a positive COVID-19 test. A computed tomography (CT) scan of the chest demonstrated peripheral bilateral ground-glass opacities, areas of consolidation, crazy paving, and fibrous interstitial bands (Figure 1A). These findings were consistent with severe COVID-19 pneumonia. She was treated with a combination of dexamethasone (8 mg daily for 10 days), convalescent plasma (600 ml per day for 2 days), and tocilizumab (400 mg per day for 2 days) and discharged 2 weeks later after her arterial blood gases had returned to normal values.

Two days after the patient was discharged home, the family contacted our office through teleconsultation regarding a persistent shortness of breath. Since arterial blood gases were difficult to obtain at home, the patient was monitored through pulse oximetry with an initial SatO2 of 93%. Low flow oxygen through nasal cannula was initiated and her oxygenation improved to an average of 97%. After 20 days, the oxygen was discontinued. She also underwent home-based pulmonary rehabilitation for 6 weeks which slightly improved her dyspnea. At her follow-up consultation 1 month after discharge, she had persistent dyspnea, fatigue, and dry cough. Pulmonary function tests (PFTs) were ordered which revealed a severe restrictive pattern and significant oxygen desaturation in the 6-min walk test (6-MWT; Table 1). Pulmonary rehabilitation was continued, and prednisone was initiated at 40 mg/day, which was slowly tapered over 4 months. The follow-up at 8 months since discharge was remarkable for persistent dry cough and slight improvement in her dyspnea. Her PFTs remained abnormal (Table 1), and a subsequent CT scan revealed that more than half of the initial opacities had improved. However, interlobular septal thickening and ground-glass opacities persisted (Figure 1B).

2.2 | Case 2

A 60-year woman presented to the E.R with a weeklong history of worsening dyspnea, chest pain, and fatigue. Her past medical history was remarkable only for obesity and a sedentary lifestyle. She had an oxygen saturation of 86% at room air and a respiratory rate of 32/min. Despite the severity of her symptoms, the patient was sent home due to hospital oversaturation, prescribed with symptomatic medication, and advised that a CT scan was needed. Follow-up teleconsultations were conducted to guide her management as best as possible given the circumstances. On her initial CT scan, bilateral ground-glass opacities and consolidations across both lung fields were noticed (Figure 2A). Her laboratory results were consistent with the inflammatory markers seen in severe COVID-19, and a positive PCR test confirmed the diagnosis. She was managed with the help of a registered nurse and received methyl-prednisolone (250 mg every 24 h for 3 days), followed by prednisone (40 mg for 7 days which was slowly tapered over 3 days), nitazoxanide (500 mg every 8 h for 7 days), colchicine (2 mg loading dose followed by 0.5 mg every 8 h for 12 days), and oxygen through nasal cannula.
Two weeks later, she presented with marked clinical improvement, which prompted the discontinuation of medications and oxygen therapy. However, she still reported shortness of breath on exertion and had persistent opacities on her follow-up CT. Due to these findings, the patient was referred for pulmonary rehabilitation and prednisone was initiated, the latter of which was tapered over 4 months. Pulmonary function tests were ordered at subsequent follow-ups and were consistent with a restrictive pattern (Table 1). Also, her diffusing capacity for carbon dioxide (DLCO) remained consistently low until the last month of follow-up. On the other hand, the 6-min walk test had slight improvement over time. A CT scan was performed 12 months since the first one was consistent with fibrotic changes across both lung fields (Figure 2A).

### DISCUSSION

Although our understanding of the potential long-term effects of COVID-19 might be limited for now, physicians are observing persisting symptoms and unexpected organ dysfunction related to the virus. A previous study that followed individuals for as long as 9 months after illness found that roughly 30% of patients reported persistent symptoms of which fatigue was the most common. In the same study, authors also found that 29% of patients reported worsened quality of life. These findings are consistent with existing literature and suggest the possibility of various sequelae among patients who recover.

In addition, new evidence is emerging of changes in the lung function after recovery from COVID-19. A recent systematic review and meta-analysis found that a considerable proportion of post-infection patients had some degree of impairment in their lung function consistent with a restrictive pattern, while the most important parameter affected was the diffusion capacity of the lungs. Similarly, both of our patients had a restrictive pattern with marked alteration of the DLCO until the 8th and 10th month of follow-up, respectively. Guidelines suggest monitoring patients with severe COVID-19 disease with full PFTs until 12 weeks after discharge. Based on our findings, the alteration in PFTs appears to persist well beyond the suggested timeframe. Whether continued long-term follow-up through PFTs is warranted in selected cases remains to be determined.

Additionally, studies have shown persistent abnormalities in chest imaging following hospital discharge, such as subpleural/peribronchial consolidations, ground-glass opacities, and traction bronchiectasis; these findings may reflect some degree of parenchymal fibrosis which is consistent with the observed changes in the respiratory function. It remains unclear whether these lesions are irreversible since data from long-term follow-up are limited and studies on the subject are still ongoing. In both of our cases, the degree of parenchymal affectation improved over time, but there were some changes that persisted up to the last month of follow-up. Further studies are needed to ascertain the true extent of structural lung changes after COVID-19, and more importantly whether treatment and pulmonary rehabilitation could help in reducing the progression ILD.

### TABLE 1 Spirometry, DLCO, and 6-min walk test of the two cases

| Case 1 | Case 2 |
|--------|--------|
| 2nd mo. | 6th mo. | 8th mo. | 3rd mo. | 6th mo. | 12th mo. |
| Abs. | Pred. | Abs. | Pred. | Abs. | Pred. | Abs. | Pred. | Abs. | Pred. | Abs. | Pred. |
| FEV1/FVC (%) | 86.9 | 115% | 81.4 | 107% | 82.9 | 109% | 0.9 | 111% | 81.7 | 104% | 79 | 105% |
| FVC (L) | 1.08 | 50% | 1.65 | 82% | 1.58 | 78% | 1.1 | 40% | 1.38 | 52% | 1.75 | 87% |
| FEV1 (L) | 0.94 | 57% | 1.34 | 90% | 1.31 | 87% | 0.9 | 44% | 1.13 | 54% | 1.39 | 93% |
| DLCO | 5.2 | 31% | 7.8 | 46% | 7.2 | 43% | 8.3 | 41% | 11.7 | 58% | 10.7 | 63% |
| TLC sb (L) | 1.83 | 58% | 2.47 | 78% | 2.15 | 68% | 2 | 51% | 2.86 | 72% | 2.76 | 87% |
| 6-MWT | 176 | 39% | – | – | 427 | 94% | 264 | 55% | 359 | 75% | 362 | 75% |
| Basal SpO2 (%) | 94% | N/A | – | – | 94% | N/A | 93% | N/A | 97% | N/A | 98% | N/A |
| Post-ex. SpO2 (%) | 83% | N/A | – | – | 91% | N/A | 88% | N/A | 96% | N/A | 97% | N/A |

Abbreviations: 6-MWT, 6-min walk test; DLCO, diffusing capacity of carbon monoxide; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; Post-ex, post expiratory; SpO2, oxygen saturation; TLC, total lung capacity.
To date, there is no specific consensus on how to treat suspected ILD following COVID-19 infection. A previous study suggested that early treatment with corticosteroids was well-tolerated and associated with rapid and significant improvement among patients with persistent inflammatory ILD following COVID-19 infection. Treatment with corticosteroids has been associated with a reduced mortality in the acute setting; however, its role as a therapy for ILD remains unclear. In the case of other agents, antifibrotic therapies may have the potential of preventing patients with severe COVID-19 from developing pulmonary fibrosis and treating those that do occur. Evidence is limited, but there are some reports on the use of antifibrotic therapies in these patients. A previous case report showed significant clinical improvement in a 78-year-old patient with suspected ILD following severe COVID-19 after 3 months of treatment with nintedanib. Another case-control study analyzing similar patients reported that the nintedanib group had noticeable improvement in CT volumetry when compared to the control group. These studies offer a cautiously optimistic view on the potential of antifibrotic therapies; however, ongoing clinical trials may soon offer more evidence to justify their use.

### 4 | CONCLUSION

There appear to be persistent abnormalities on pulmonary function tests and imaging following severe COVID-19 disease in some patients. These abnormalities may include a restrictive pattern, a reduced diffusing capacity for carbon monoxide of the lungs, and structural abnormalities compatible with interstitial lung disease.

### ACKNOWLEDGEMENTS

Special thanks to Universidad Espíritu Santo for their continuous support in the field of medical research.

### CONFLICT OF INTEREST

I declare on behalf of my co-authors and myself that we do not have any conflict of interest to declare related to this work.

### AUTHOR CONTRIBUTIONS

ICO, KRV, MFO, and MF developed the research question for the case report. KRV and MFO participated in the data recollection process. KR, MFO, VC, JVC, and MF wrote the final manuscript. All authors read and approved the final version.

### CONSENT

Written informed consent was obtained from the patient for the publication of the case report and any accompanying images. A copy of the written consent is available for review by editors if required.

### DATA AVAILABILITY STATEMENT

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

### ORCID

Ivan Cherrez-Ojeda [https://orcid.org/0000-0002-1610-239X](https://orcid.org/0000-0002-1610-239X)

Miguel Felix [https://orcid.org/0000-0002-2243-3646](https://orcid.org/0000-0002-2243-3646)

### REFERENCES

1. World Health Organization. WHO coronavirus (COVID-19) dashboard. [https://covid19.who.int/](https://covid19.who.int/)
2. George PM, Wells AU, Jenkins KG. Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. *Lancet Respir Med*. 2020;8:807-815.
3. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020;395:497-506.

4. Zhang P, Li J, Liu H, et al. Long-term bone and lung consequences associated with hospital-acquired severe acute respiratory syndrome: a 15-year follow-up from a prospective cohort study. *Bone Res.* 2020;8:1-8.

5. Cortinovis M, Perico N, Remuzzi G. Long-term follow-up of recovered patients with COVID-19. *Lancet*. 2021;397:173-175.

6. Logue JK, Franko NM, McCulloch DJ, et al. Sequelae in adults at 6 months after COVID-19 infection. *JAMA Netw Open*. 2021;4:e210830-e210830.

7. van der Sar-van der Brugge S, Talman S, Boonman-de Winter L, de Mol M, Hoefman E, van Etten RW. Pulmonary function and health-related quality of life after COVID-19 pneumonia. *Respir Med*. 2021;176:106272.

8. Garrigues E, Janvier P, Kherabi Y, et al. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. *J Infect*. 2020;81:e4-e6.

9. Torres-Castro R, Vasconcello-Castillo L, Alsina-Restoy X, et al. Respiratory function in patients post-infection by COVID-19: a systematic review and meta-analysis. *Pulmonology*. 2021;27(4):328-337.

10. British Thoracic Society. British thoracic society guidance on respiratory follow up of patients with a clinico-radiological diagnosis of COVID-19 pneumonia. *Br Thorac Soc*. 2020;1–15.

11. Huang Y, Tan C, Wu J, et al. Impact of coronavirus disease 2019 on pulmonary function in early convalescence phase. *Respir Res*. 2020;21:1-10.

12. Myall KJ, Mukherjee B, Castanheira AM, et al. Persistent post–COVID-19 interstitial lung disease. An observational study of corticosteroid treatment. *Ann Am Thorac Soc*. 2021;18:799-806.

13. Susanto AD, Triyoga PA, Isbaniah F, et al. Lung fibrosis sequelae after recovery from COVID-19 infection. *J Infect Dev Ctries*. 2021;15:360-365.

14. Ogata H, Nakagawa T, Sakoda S, et al. Nintedanib treatment for pulmonary fibrosis after coronavirus disease 2019. *Respirol Case Rep*. 2021;9:e00744.

15. Umemura Y, Mitsuyama Y, Minami K, et al. Efficacy and safety of nintedanib for pulmonary fibrosis in severe pneumonia induced by coronavirus disease 2019: an interventional study. *Int J Infect Dis*. 2021;108:454-460.

16. Spagnolo P, Balestro E, Aliberti S, et al. Pulmonary fibrosis secondary to COVID-19: a call to arms? *Lancet Respir Med*. 2020;8:750-752.

**How to cite this article:** Cherrez-Ojeda I, Robles-Velasco K, Osorio MF, Cottin V, Vergara Centeno J, Felix M. Follow-up of two cases of suspected interstitial lung disease following severe COVID-19 infection shows persistent changes in imaging and lung function. *Clin Case Rep*. 2021;9:e04918. [https://doi.org/10.1002/ccr3.4918](https://doi.org/10.1002/ccr3.4918)